Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BARD C R INC /NJ/BCR · Entity 170698 | Director | December 29, 2017 | January 03, 2018 |
| Duke Energy CORPDUK · Entity 2925 | Director | May 07, 2026 | May 11, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Director · Chairman, CEO & President | May 05, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BARD C R INC /NJ/
Report date December 29, 2017 · Filed January 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 1
1 source rowRow 1 · 2017-12-29 · Disposition to issuer · Disposed 1,302 · Balance 0 F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). |
| Share Equivalent UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-12-29 · Disposition to issuer · Disposed 1,062 · Balance 0 F2: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F3: Conversion is 1 for 1. F4: These units, which are 100% vested, were assumed by BD at the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration").
F2: Units granted under the Company's Stock Equivalent Plan for Outside Directors.
F3: Conversion is 1 for 1.
F4: These units, which are 100% vested, were assumed by BD at the effective time of the Merger.
Duke Energy CORP
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,262 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 1,602 · Balance 14,262 |
Merck & Co., Inc.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2029-05-05 | Direct | 47,724 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Grant · Acquired 47,724 · Balance 47,724 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.15 · Expires 2036-05-04 | Direct | 139,697 |
Reported balance
After 2026-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-05 · Grant · Acquired 139,697 · Balance 139,697 F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Common StockSEC Table I · non-derivative | Direct | 450,350.757 |
Reported balance
Holding disclosure · report date 2026-05-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 450,350.757 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2019 Filed Jun 27, 2019 21:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 190,168 | $85.35 | $16,230,686.67 |
DisclosureSEC source: 0001127602-19-022966 · form4.xml · nonDerivative · entry 2 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,209.757 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.8500 to $85.8400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 21:05 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 216,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022966 · form4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,377.757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 112,907 | $0.00 Strike: $80.00 | $0.00 |
DisclosureSEC source: 0001104659-19-027580 · a4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · Evp, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,907 Underlying: Common Stock · 112,907 shares Expires 2029-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 02, 2019 Filed May 6, 2019 20:39 UTC | Duke Energy CORP DUK · Entity 2925 | GrantCommon Stock | 1,781.539 | $89.81 | $160,000.02 |
DisclosureSEC source: 0001326160-19-000137 · wf-form4_155717515348519.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,396.539 Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 21:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 192,572 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-19-005843 · doc4.xml · derivative · entry 3 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192,572 shares Expires 2024-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/9/2015, 5/9/2016 and 5/9/2017. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 21:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 192,572 | $82.38 | $15,863,118.50 |
DisclosureSEC source: 0001225208-19-005843 · doc4.xml · nonDerivative · entry 2 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,659.757 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.9300 to $82.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 21:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 192,572 | $58.22 | $11,211,541.84 |
DisclosureSEC source: 0001225208-19-005843 · doc4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,231.757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 30,610 | $80.38 | $2,460,431.80 |
DisclosureSEC source: 0001225208-19-003891 · doc4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,659.757 F1 · shares: Distrubtion of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/16. Performance shares were paid out at 126 percent of target awards. Includes dividends accured over the three-year performance period ending December 31, 2018. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 139,063 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008933 · doc4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,063 Underlying: Common Stock · 139,063 shares Expires 2028-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:33 UTC | Duke Energy CORP DUK · Entity 2925 | GrantDirector Savings Plan Restricted Stock Unit Deferrals · Derivative | 2,006.018 | $79.76 | $160,000.00 |
DisclosureSEC source: 0001326160-18-000115 · wf-form4_152572522557993.xml · derivative · entry 1 Davis Robert M · CIK 0001363076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,006.018 Underlying: Common Stock · 2,006.018 shares Expires not disclosed F1 · derivative.exercise_price: Converts to Common Stock on a 1-for-1 basis. F2 · derivative.exercise_date: Generally payable upon reporting person's termination of service. F3 · derivative.expiration_date: Expiration date not applicable. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 30,908 | $54.72 | $1,691,285.76 |
DisclosureSEC source: 0001225208-18-005018 · doc4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,128.164 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 21:45 UTC | Duke Energy CORP DUK · Entity 2925 | GrantCommon Stock | 614.951 | $82.20 | $50,548.97 |
DisclosureSEC source: 0001326160-18-000004 · wf-form4_151553430162867.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614.951 Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 18:36 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | Disposition to issuerShare Equivalent Units · Derivative | 1,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-18-000474 · doc4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,062 shares Expires not disclosed F2 · security: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F3 · derivative.exercise_price: Conversion is 1 for 1. F4 · price: These units, which are 100% vested, were assumed by BD at the effective time of the Merger. F4 · derivative.exercise_date: These units, which are 100% vested, were assumed by BD at the effective time of the Merger. F4 · derivative.expiration_date: These units, which are 100% vested, were assumed by BD at the effective time of the Merger. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 18:36 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | Disposition to issuerCommon Stock | 1,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000474 · doc4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 15:05 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantShare Equivalent Units · Derivative | 245 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018185 · doc4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062 Underlying: Common Stock · 245 shares Expires not disclosed F2 · security: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F3 · derivative.exercise_price: Conversion is 1 for 1. F4 · derivative.exercise_date: Share Equivalent Units are settled in cash upon termination as a director. F4 · derivative.expiration_date: Share Equivalent Units are settled in cash upon termination as a director. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 15:05 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantCommon Stock | 298 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018185 · doc4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,302 F1 · kind: Stock award granted in accordance with the 2005 Directors' Stock Award Plan, as amended and restated, that fully vests in three years from the date of grant, subject to earlier acceleration. Read SEC document |
| May 09, 2017 Filed May 9, 2017 20:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 85,881 | $64.01 | $5,497,242.81 |
DisclosureSEC source: 0001225208-17-009424 · doc4.xml · derivative · entry 4 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,881 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 09, 2017 Filed May 9, 2017 20:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 44,530 | $64.01 | $2,850,365.30 |
DisclosureSEC source: 0001225208-17-009424 · doc4.xml · nonDerivative · entry 2 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500.943 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 09, 2017 Filed May 9, 2017 20:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 85,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009424 · doc4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,030.943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 162,625 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009424 · doc4.xml · derivative · entry 3 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,625 Underlying: Common Stock · 162,625 shares Expires 2027-05-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 31,913 | $65.85 | $2,101,471.05 |
DisclosureSEC source: 0001225208-17-005083 · doc4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · EVP, Global Svcs & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,913 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 5/9/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 15:58 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantShare Equivalent Units · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-043306 · doc4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817 Underlying: Common Stock · 375 shares Expires not disclosed F2 · security: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F3 · derivative.exercise_price: Conversion is 1 for 1. F4 · derivative.exercise_date: Share Equivalent Units are settled in cash upon termination as a director. F4 · derivative.expiration_date: Share Equivalent Units are settled in cash upon termination as a director. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 15:58 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantCommon Stock | 468 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-043306 · doc4.xml · nonDerivative · entry 1 Davis Robert M · CIK 0001363076 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,004 F1 · kind: Stock award granted in accordance with the 2005 Directors' Stock Award Plan, as amended and restated, that fully vests in three years from the date of grant. Read SEC document |
| May 10, 2016 Filed May 12, 2016 15:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 251,273 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-16-033214 · doc4.xml · derivative · entry 1 Davis Robert M · CIK 0001363076 · EVP, CFO & Global Svcs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,273 Underlying: Common Stock · 251,273 shares Expires 2026-05-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| May 01, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 216,718 | $0.00 Strike: $59.86 | $0.00 |
DisclosureSEC source: 0001225208-15-011283 · doc4.xml · derivative · entry 1 Davis Robert M · CIK 0001363076 · Exec V-P & Chief Fince Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,718 Underlying: Common Stock · 216,718 shares Expires 2025-04-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:52 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 192,572 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-14-012815 · doc4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · Exec V-P & Chief Fince Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,572 Underlying: Common Stock · 192,572 shares Expires 2024-05-08 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:52 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 85,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-012815 · doc4.xml · derivative · entry 1 Davis Robert M · CIK 0001363076 · Exec V-P & Chief Fince Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,881 Underlying: Common Stock · 85,881 shares Expires 2017-05-09 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.